Media Inquiries

Meredith Kaya

Vice President, Investor Relations and Corporate Communications

617.374.5082

mkaya@ironwoodpharma.com

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

bcalitri@ironwoodpharma.com
Sort by Year
December 4, 2017

Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects

November 28, 2017

Ironwood Pharmaceuticals Strengthens Executive Leadership Team

November 2, 2017

Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update

November 1, 2017

Ironwood Pharmaceuticals to Present at Credit Suisse 26th Annual Healthcare Conference

October 30, 2017

Ironwood Highlights Breadth of Gout Research to be Presented at the 2017 ACR/ARHP Annual Meeting

October 19, 2017

Ironwood Pharmaceuticals to Host Third Quarter 2017 Investor Update Call

October 16, 2017

Ironwood Pharmaceuticals Presenting Linaclotide Data at the World Congress of Gastroenterology at ACG 2017

September 6, 2017

Ironwood Pharmaceuticals Announces Leadership Change

August 31, 2017

Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences

August 21, 2017

Ironwood Pharmaceuticals Announces FDA Approval of DUZALLO® (lesinurad and allopurinol) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout

August 3, 2017

Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update

July 20, 2017

Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease

July 20, 2017

Ironwood Pharmaceuticals to Host Second Quarter 2017 Investor Update Call

June 8, 2017

Ironwood Pharmaceuticals to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

June 1, 2017

Ironwood Pharmaceuticals to Present at the Jefferies Healthcare Conference

Copyright © 2020, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.